Drug Interaction Report

mitoMYcin has a major potential interaction with Bleeding Disorder.

The use of mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorders, or an increase in bleeding tendency. Mitomycin induces cumulative, delayed myelosuppression. Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy. Therapy with mitomycin should be withheld if platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.

mitoMYcin has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Mitomycin induces cumulative, delayed myelosuppression. Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy. Anemia occurs less frequently. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended. Therapy with mitomycin should be withheld if white blood cell counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.

The rotavirus vaccine in RotaShield has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

The safety and efficacy of rotavirus vaccine in infants with known primary or secondary immunodeficiencies, including HIV, infants in immunosuppressant therapy, or infants with malignant neoplasm affecting the bone marrow or lymphatic system has not been established. Caution is advised when considering wether to administer this vaccine to such patients or patients with immunodeficient close contacts as there is a potential of transmission of the virus through shedding in stools after vaccination (peak excretion occurring around day 7 after first dose).

mitoMYcin has a major potential interaction with Coagulation Defects and Disorders.

The use of mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorders, or an increase in bleeding tendency. Mitomycin induces cumulative, delayed myelosuppression. Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy. Therapy with mitomycin should be withheld if platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.

The rotavirus vaccine in RotaShield has a moderate potential interaction with Diarrhea.

The administration of the rotavirus vaccine should be delayed in infants suffering from acute diarrhea or vomiting. Additionally, the effectiveness of this vaccine has not been evaluated in infants with chronic gastrointestinal disorders.

mitoMYcin has a major potential interaction with Fever.

Mitomycin induces cumulative, delayed myelosuppression. Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy. Anemia occurs less frequently. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended. Therapy with mitomycin should be withheld if white blood cell counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.

The rotavirus vaccine in RotaShield has a major potential interaction with Immunodeficiency.

The safety and efficacy of rotavirus vaccine in infants with known primary or secondary immunodeficiencies, including HIV, infants in immunosuppressant therapy, or infants with malignant neoplasm affecting the bone marrow or lymphatic system has not been established. Caution is advised when considering wether to administer this vaccine to such patients or patients with immunodeficient close contacts as there is a potential of transmission of the virus through shedding in stools after vaccination (peak excretion occurring around day 7 after first dose).

mitoMYcin has a major potential interaction with Infection.

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

The rotavirus vaccine in RotaShield has a major potential interaction with Lymphoma.

The safety and efficacy of rotavirus vaccine in infants with known primary or secondary immunodeficiencies, including HIV, infants in immunosuppressant therapy, or infants with malignant neoplasm affecting the bone marrow or lymphatic system has not been established. Caution is advised when considering wether to administer this vaccine to such patients or patients with immunodeficient close contacts as there is a potential of transmission of the virus through shedding in stools after vaccination (peak excretion occurring around day 7 after first dose).

mitoMYcin has a major potential interaction with Renal Dysfunction.

Elevations in BUN and/or serum creatinine have been reported during mitomycin therapy. Therapy with mitomycin should not be administered to patients with serum creatinine > 1.7 mg/dl. Hemolytic Uremic Syndrome (HUS) has been reported during mitomycin therapy. The incidence of HUS appears to be increased in patients receiving total doses of mitomycin > 60 mg. Blood product transfusion may exacerbate the symptoms of HUS. Clinical monitoring of renal function is recommended.

The rotavirus vaccine in RotaShield has a moderate potential interaction with Vomiting.

The administration of the rotavirus vaccine should be delayed in infants suffering from acute diarrhea or vomiting. Additionally, the effectiveness of this vaccine has not been evaluated in infants with chronic gastrointestinal disorders.